• Dr. Reddy's received tentative U.S. FDA approval under PEPFAR for twice-yearly injectable lenacapavir for HIV prevention.
• Pricing is set at US$ 40 per person annually across 120 countries outside the U.S. under Gilead's voluntary license.
• Initial supplies are expected by end-2026, with broader availability in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dr. Reddy's Laboratories Limited published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.